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Ra-223 or placebo respectively. Patients entered the model progression-free, 
receiving active treatment until progression or completion of the therapy course. 
Health states reflected patients experiencing first or subsequent SRE. In the trial, 
SRE was defined as treatment with external-beam radiation therapy (EBRT), 
surgical intervention, occurrence of pathological bone fracture, or spinal cord 
compression. A 5-year time horizon was considered. Costs were estimated from 
a US payer perspective. SRE costs were obtained by multiplying the number  
of patients experiencing SRE by its specific treatment cost (including 
hospitalization costs). RESULTS: Ra-223 increased mean life expectancy by 0.325 
(95% CI: 0.324-0.326) years in the ITT population and 0.517 (95% CI: 0.516-0.518) 
years in the subgroup of patients who had not received first-line docetaxel.  
Ra-223 was projected to lead to 44% reduction in the cost of treatment of SREs 
versus BSC: 46% reduction in pathologic bone fracture costs; 48% for spinal  
cord compression; 16% for external beam radiation; and 11% for  
surgical interventions. A total of 32.9% of patients suffered a first SRE for Ra-223 
versus 37.8% for placebo and 6.5% and 7.8%, respectively, suffered two or more 
SRE events. CONCLUSIONS: In patients treated with BSoC, Ra-223 reduced  
costs of SREs. Future studies will evaluate the total cost of care related to  
the benefit of Ra-223 versus placebo in patients treated with BSoC in  
mCRPC once the cost of therapy and the impact on quality adjusted survival are 
known.  
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OBJECTIVES: Validated companion diagnostic assays permit collection of critical 
clinical data that leads to actionable treatment decisions and better patient 
outcomes. The cobas BRAF test is an FDA-approved companion diagnostic that 
identifies V600 mutation positive malignant melanoma to determine patient 
eligibility for treatment with vemurafenib. Sanger sequencing is also a validated, 
lab developed test that provides similar information for the gene encoding the 
BRAF protein. Test performance differences can have an impact on patient 
outcomes and overall cost of testing and treatment. METHODS: Based on assay 
performance data for both tests, generated during the phase 2 BRIM-2 (N=132), 
BRIM-2/3 (N=433) and phase 3 BRIM-3 (N=449) studies, an integrated drug-
diagnostic budget impact model was developed from a third-party payer 
perspective assuming a 6-month treatment period. Cost estimates were based on 
testing 100% unresectable stage III-IV melanomas assuming 50% incidence of 
BRAF mutations. Diagnostic costs were based on reimbursement for average 
code-stacks across various lab and therapeutic costs for vemurafenib (and 
ipilimumab) were inclusive of administrative and adverse event costs. Sensitivity 
models were run to estimate costs across a wide range of values for the various 
model parameters. RESULTS: Overall, the sum of invalid tests, false positive and 
false negative results across all 3 studies was 14.6% (148/1014) for Sanger 
sequencing and 0.6% (6/1014) for the cobas BRAF test. Use of the cobas BRAF test 
versus Sanger sequencing resulted in total saving of $14.2 million or $1,479.17 
per patient in the BRIM-3 study and $21.9 million or $2,281.25 per patient in the 
BRIM2/3 dataset. Savings were primarily a result of avoiding unnecessary or 
inappropriate drug therapy and diagnostic costs accounted for a small fraction 
(0.13-0.29%) of total expenditures. CONCLUSIONS: Use of the clinically validated 
and more accurate cobas BRAF test resulted in significant cost savings relative to 
Sanger sequencing for BRAF mutations.  
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OBJECTIVES: Ifosfamide, a key chemotherapy for advanced stages of the  
rare cancer soft-tissue sarcoma (STS), is a generic medication. However, 
administration often entails hospitalization and adjuvant mesna as prophylaxis 
against hemorrhagic cystitis; resultant costs are unknown. This study examined 
health care costs and its drivers for managed care patients with STS who were 
treated with ifosfamide and other chemotherapies. METHODS: We 
retrospectively studied administrative claims of adult STS patients in a large US 
managed care plan who initiated chemotherapy between 2000−2011. The first 
chemotherapy treatment following diagnosis identified in medical claims was 
categorized by setting of chemotherapy initiation (ambulatory or hospital). 
Health care utilization and costs were identified over a 1-year follow-up 
(retaining patients dying prior to 1 year); patient/clinical characteristics were 
assessed over a 6-month baseline. Analyses included descriptive statistics and 
ordinary least squares on logged costs adjusted for patient/clinical 
characteristics (retransformed with smearing estimator). RESULTS: Ifosfamide-
treated patients (alone, n=18, or combined with doxorubicin, n=47) were younger 
compared to the 149 patients in 4 other chemotherapy cohorts: means 50-52, 
versus 58 years for the next youngest (doxorubicin, gemcitabine+docetaxel 
cohorts), p=0.004. Total health care costs were significantly higher for ifosfamide 
cohorts (adjusted means $ 115,559 and $ 129,537) versus other cohorts except for 
gemcitabine+docetaxel (means ranged from $73,496 to $117,451, p<0.05). 
Differences in medical costs were due to higher ambulatory and inpatient 
expenditures for ifosfamide cohorts, which generally had higher numbers of 
visits including inpatient visits: ifosfamide means 0.94, 1.49, versus other cohorts 
0.65, 0.72, 0.81, and 1.51 (gemcitabine+docetaxel), p<0.016. CONCLUSIONS: 
Patients with STS treated with ifosfamide had significantly higher health care 
costs than did patients treated with most other chemotherapies, suggesting that 
although a generic medication, ifosfamide may impose a higher disease 
management burden and impact on health plan budgets. Whether emerging 
therapies will result in lower health care costs warrants exploration.  
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OBJECTIVES: Incidence of hepatocellular carcinoma (HCC) is increasing in the 
U.S. and worldwide. Several treatments are available for patients newly 
diagnosed with the disease. We examine cumulative Medicare-paid expenditures 
and survival associated with various treatment modalities for HCC in a 
population for which it is most treated. METHODS: Medicare enrollees with an 
initial diagnosis of primary HCC between 2000-2007 were followed through 2009. 
Data are from SEER and linked Medicare databases, with claims generated from 
Parts A and B. Multivariate Cox proportional hazards models were used to 
estimate risk and calculate mean all-cause/HCC-related survival associated with 
transplant, resection, liver directed therapy, radiation, systemic chemotherapy 
or no treatment. Partitioned inverse probability-weighted least squares 
regression estimated cumulative Medicare expenditures adjusted for censoring 
and covariates. Bootstrapping was used to obtain 95% Confidence Intervals for 
cost estimates. RESULTS: Cancer stages one, two, three and four represented 
24%, 9%, 14%, and 17% of the 11,047 patients, respectively. Nearly one-third (37%) 
were unstaged, 66% were male, 75% Caucasian, 10% African American; 60% of 
patients were untreated, 16% liver directed, 8% chemotherapy, 8% resection, 4% 
radiation, and 4% transplant. Using all-cause (HCC-related) mortality, transplant 
patients incurred an average $263,296 [95%CI: $244,200-$282,392] over an average 
5.47 (6.9) years, resection $131,812 [$126,770-$136,854] over 3.5 (5.1) years, liver 
directed $91,488 [$88,749-$94,227] over 2.2 (3.8) years, chemotherapy $55,379 
[$53,442-$57,316]over 1.2 (2.8) years, radiation $58,308 [$55,355-$61,261] over 1.2 
(2.6) years, and no treatment $27,937 [$27,355-$28,519] over 0.6 (1.1) years. 
CONCLUSIONS: Cumulative Medicare expenditures were over 9x higher for 
transplant versus no treatment, nearly 5x for resection, over 3x for liver directed, 
and nearly double for chemotherapy or radiation, even after adjusting for cancer 
stage and other confounders. Differences in Medicare spending between 
treatment modalities were nearly proportional to differences in (all-cause) years 
survived after HCC diagnosis.  
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OBJECTIVES: Colorectal cancer is the third highest incidence amongst all cancers 
worldwide. Biologics are increasingly used as a treatment option, and due to 
high associated drug cost HMOs need to minimize expenditures by choosing less 
costly treatment strategies. Real-world data is growing in importance in health 
care decision making especially in coverage and reimbursement decisions. 
Therefore, the objective of the study is support treatment decision making by 
providing evidence based on real-world data, focusing on most used biologics in 
metastatic CRC: bevacizumab and cetuximab. METHODS: A review of 
administrative claims database of Unimed São José do Rio Preto (medical 
cooperative responsible for 118,000 lives in São Paulo-Brazil) was conducted for 
patients who underwent CRC treatment between December 2009 through 
January 2012. In order not to disclose confidential commercial arrangements 
with suppliers analysis were focused on total costs of treatment (drugs, 
devices/materials and room taxes). In the cases where a single patient 
underwent treatment with more than one biologic the analysis was performed 
considering the different regimens for the patient, obtaining daily 
costs/regimen/patient, and then converted on monthly basis. Focus was given to 
costs related to bevacizumab plus chemotherapy (Bev+CT) and cetuximab plus 
chemotherapy (Cet+CT) regimens. Also, regimens were classified into irinotecan 
or oxaliplatin-based. Costs were reported in Brazilian Reais (BRL1.00~USD0.48 
December 2012). RESULTS: A total of 108 CRC patients were identified and 
regimens were 22.7% Bev+CT and 16.3% Cet+CT. Approximately 80% of both 
biological drugs were combined with irinotecan-based schemes. Average 
cost/patient/month were BRL 12,585 (SD: BRL3,588) for Bev+CT and BRL 17,178 
(SD: BRL3,797) for Cet+CT. CONCLUSIONS: Results indicate potential resource 
savings favoring bevacizumab. If all patients treated with cetuximab were 
treated with bevacizumab instead, it could averagely result in savings of BRL 
64,301 per month (less 26.7%). Study had limitation regarding identification of 
treatment line and sample size precluded identification of statistical difference 
between treatments.  
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OBJECTIVES: Abiraterone acetate (AA), a selective androgen biosynthesis 
inhibitor, blocks the action of CYP17, thereby inhibiting adrenal and intratumoral 
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androgen synthesis. In a preplanned interim analysis of the Phase 3 trial COU-
AA-301, AA plus prednisone (P) showed a significant overall survival (OS) benefit 
of 3.9 months vs placebo plus P (de Bono, NEJM 2011). A preplanned and updated 
analysis showed that the improvement in median OS increased from 3.9 months 
to 4.6 months (HR = 0.74) (Fizazi, Lancet Oncol 2012). The purpose of this study 
was to evaluate the cost effectiveness of AA vs P using data from Swedish 
patients. METHODS: A survival-based decision analysis model was developed 
incorporating 3 health states: progression-free survival, post-progression 
survival, and OS (indirect comparison). The cost-effectiveness model was 
populated with data from one placebo-controlled randomized clinical trial in 
which AA was an add-on to P (de Bono, NEJM 2011), and treatment duration from 
the name-patient-programme (NPP) in Sweden for patients with metastatic 
castrate-resistant prostate cancer post-docetaxel. Resource utilization and costs 
reflected Swedish treatment conditions within a broad societal perspective. Drug 
costs per 3-week-model-cycle were $3180 (€2300) and $53 (€41) for AA and P, 
respectively. RESULTS: Total costs per patient were $85270 (€67300) and $52700 
(€41600) for AA and P, respectively. Quality-adjusted life years (QALYs) were 1.24 
and 0.77 for AA and P, respectively. CONCLUSIONS: The results show that AA 
treatment compared to P has a cost per QALY gained of $69800 (€55000). AA 
provides an OS benefit with a highly manageable and benign safety profile, 
compared to P, which has negligible effects on OS and QoL.  
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OBJECTIVES: Approximately 2.8 million American men have a history of prostate 
cancer, the most prevalent cancer among men in the US. This study quantified 
the effects of prostate cancer on direct health care costs to insurers and patients. 
METHODS: Using data 1996-2009 from the Medical Expenditure Panel Survey 
(MEPS), a large, nationally-representative database from the US, this study 
performed multivariate analyses of the relationship between prostate cancer and 
direct annual health care costs to insurers and patients, at individual and US 
aggregate levels. All men age 40 and older with International Classification of 
Disease Codes, 9th revision of 185 were identified. RESULTS: The MEPS database 
included 1,399 patients with prostate cancer. Mean age was 72 years, and 71% 
were Caucasian. Prostate cancer patients incurred $9,300 more in overall annual 
health care costs per patient when compared to non-prostate cancer patients 
($18,423 vs. $9,093). The majority of direct health care costs were borne by the 
insurer ($8,900) rather than the patient ($430). Prostate cancer had a larger effect 
on incremental costs for younger patients ($16,253 40-64 years vs. $10,236 65-74 
years; $7,767 75+ years). When aggregated to the US population, prostate cancer 
accounted for an incremental annual cost of $14.27 billion. The largest aggregate 
costs were incurred by patients aged 40-64 years ($5.33 billion), compared to 
those aged 65-74 ($4.86 billion) and patients aged 75+ ($4.08 billion). 
CONCLUSIONS: These findings indicate that the cost burden from prostate 
cancer is quite large. Younger patients incur more direct health care costs, 
possibly due to more aggressive treatment practices, which may be related to 
more aggressive tumor burden. With aging of the population, prevalence of 
prostate cancer is expected to increase to 3.2 million in the US in 2020. Further 
research to understand these cost implications is warranted.  
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OBJECTIVES: In terms of indirect cost, prostate cancer appears to have an 
adverse impact on work performance, due to the use of sick days by patients in 
the period after diagnosis. This study quantified the effects of prostate cancer on 
indirect costs related to work absence and unemployment among individuals 
age 40 and older. METHODS: Using 1996-2009 data from the Medical Expenditure 
Panel Survey (MEPS), a large, nationally-representative database from the US, we 
performed multivariate analyses evaluating the relationship between prostate 
cancer and indirect costs, at the individual and US aggregate levels. All men with 
International Classification of Disease Codes, ninth revision of 185 were 
identified. Costs by 2 age categories (40-64 years, 65+ years) were explored. 
Indirect costs were defined as lost worker productivity resulting from being 
unemployed or days of missed work as a result of illness. RESULTS: The MEPS 
database included 1,399 patients with prostate cancer. Mean age was 72 years, 
and 71% were Caucasian. Prostate cancer patients had a greater probability of 
being unemployed (40% vs. 34%) and a greater probability of missing work due to 
illness (68% vs. 47%) than non-prostate cancer patients. Employed patients with 
prostate cancer missed 9.3 more work days than individuals without prostate 
cancer (19.5 vs. 10.2). This resulted in an incremental indirect cost of $2936 per 
patient. Indirect costs due to prostate cancer were higher for patients aged 40-64 
than patients aged 65+ ($6848 versus $1581). When aggregated to the  
US population, prostate cancer accounted for $4.21 billion in indirect costs,  
with $2.68 billion for patients aged 40-64 and $1.53 billion for patients aged 65 
and older. CONCLUSIONS: These findings indicate that the indirect cost burden 
from prostate cancer is quite large, especially for younger patients. Further 
research is needed to determine the impact of disease severity on productivity-
related costs.  
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OBJECTIVES: Treatment patterns and cost of care are believed to vary 
substantially as patients with colorectal cancer (CRC) progress from first line 
through third line therapy. The aim of this study was to examine patterns and 
cost of care in these patients. METHODS: A retrospective analysis was performed 
using claims from the Optum Oncology Research Database. Patients aged 18 
years and older, diagnosed with CRC between July 1, 2004 and December 31, 
2010, who were insured by a commercial health plan were included in the study. 
Chemotherapy combinations were assessed for patients receiving first, second 
and third line of therapy for CRC; and for patients with and without metastatic 
disease. Inpatient, outpatient, chemotherapy, biologic-related, and total costs 
were compared by the Kruskal-Wallis test. RESULTS: A total of 1039 patients 
who received chemotherapy or biologic therapy for CRC were included. FOLFOX 
and fluorouracil monotherapy were the most common first-line therapies, each 
accounting for approximately 27% of patients who received any chemotherapy. 
Oxaliplatin-based regimens were most common for patients receiving second-
line therapy (45% of patients). Irinotecan-based regimens were most common 
among patients receiving third line therapy (35% of patients). The median total 
cost of care increased significantly for patients receiving first ($25,782), second 
($36,951), and third ($86,944) line therapy (p<0.0001 by Kruskal-Wallis test). 
Median costs were significantly greater for patients receiving third versus first 
line therapy for outpatient care ($39,952 vs. $15,521), inpatient care ($3,668 vs. 
$1,721 vs.), chemotherapy ($14,059 vs. $3,662) and biologic therapy ($28,824 vs. 
$4,899). Median total were significantly greater for patients with metastases 
($39,001) compared with those without ($8,989; p<0.0001). CONCLUSIONS: 
Treatment patterns vary significantly by line of therapy in patients with CRC. 
The total cost of care increased significantly as patients received additional lines 
of therapy and is significantly greater for patients with metastases compared to 
those without.  
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OBJECTIVES: Carcinoma of kidney (or renal cell carcinoma) is one common 
tumor for adults. The purpose of this study was to evaluate the direct costs of 
patients with carcinoma of kidney in China, producing an average cost per 
patient per year and the overall economic burden of the whole carcinoma of 
kidney population. METHODS: A cost-of-illness analysis was then performed. 
The Chinese Basic Medical Insurance Databases in 2010 were used to collect data 
on health care resource utilization and costs. 224 patients diagnosed with 
carcinoma of kidney were randomly selected by stratified two-stage sampling. 
All information of patient demographic characters, clinical and costs were 
collected for the analysis. Direct medical costs included were diagnostic tests, 
physiotherapy, surgery, drug and administration costs. The descriptive statistics 
was used to describe patients’ demographic characters and costs. Prevalence 
data on carcinoma of kidney for the Chinese population was collected from 
literatures. The overall economic burden of the whole carcinoma of kidney 
population was estimated based on the costs per patient per year and the 
prevalence data. All costs referred to 2010. RESULTS: Total 224 patients (mean 
age 60.9 years; 72.6% male) were evaluated. Total costs per patient over 1 year 
amounted to Chinese Yuan (CNY) 17,366 (median: CNY15750, IQR: CNY7773 –
CNY26285), with drug costs accounting for 50.14% of the total. Based the 
prevalence of carcinoma of kidney from literatures, there was about 74,809 
patients of carcinoma of kidney. Costs for the nation are estimated at CNY 0.389 
billion per year. CONCLUSIONS: The economic burden of carcinoma of kidney in 
China is considerable. The primary burden on patients was due to drugs.  
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OBJECTIVES: This study quantified the “spillover” effects of prostate cancer on 
indirect costs related to work absence and unemployment among spouses and 
other family members residing with prostate cancer patients, a topic that has 
received little attention in the literature. METHODS: Using 1996-2009 data from 
the Medical Expenditure Panel Survey (MEPS), a large, nationally-representative 
database from the US, this study performed multivariate analyses evaluating the 
relationship between prostate cancer and the indirect costs to family members 
and spouses of prostate cancer patients. Indirect costs were defined as lost 
worker productivity resulting from being unemployed or missed work-days as a 
result of prostate cancer. Spillover effects were calculated for all individual 
family members (including spouses) and for spouses separately, and projected to 
the US population. RESULTS: The MEPS database included data for 1,399 patients 
with prostate cancer, 1,121 family members and 874 spouses. Family members of 
prostate cancer patients were found to have incurred $1,319 in annual indirect 
